Silencing SF3B1 promotes apoptosis and inhibits proliferation and invasion of human lung cancer cell line A549

doi:10.16352/j.issn.1001-6325.2023.08.1265

Abstract

Abstract: Objective To explore the effect of splicing factor 3B subunit (SF3B1) on apoptosis, proliferation and invasion of human lung cancer cells. Methods Non-small cell lung cancer(NSCLC) patients in the General Hospital of Western Theater Command PLA from June 2017 to June 2020 were selected as the research objects to detect the level of SF3B1 in cancer and adjacent tissues, and to analyze the relationship between SF3B1 and the pathological characteristics, survival and prognosis of patients. In addition, A549 cells were cultured and divided into control group, transfected si-NC group and si-SF3B1 group. Cell apoptosis was detected by flow cytometry, cell proliferation was detected by CCK-8, cell invasion was detected by Transwell, and the expression of Ras/Raf/ERK signal protein was detected by Western blot. Results The level of SF3B1 mRNA in cancer tissues was significantly higher than that in adjacent tissues(P＜0.05), and its level in A549 cells was significantly higher than that in normal lung epithelial cell line BEAS-2B(P＜0.05). The high level of SF3B1 was related to lymph node metastasis, tumor size and differentiation(P＜0.05). The median overall survival(OS) and progression free survival(PFS) of patients with low expression of SF3B1 were significantly higher than those with high expression of SF3B1(P＜0.05). After silencing SF3B1, the apoptosis of A549 cells was significantly increased but the proliferation and invasion were significantly decreased. The silence of SF3B1 suppressed the expression of Ras, Raf and p-ERK in A549 cells. Conclusions SF3B1 is highly expressed in NSCLC. Silencing SF3B1 can promote lung cancer cell apoptosis, inhibit cell proliferation and invasion.

Key words: non-small cell lung cancer, splicing factor 3B subunit 1, Ras, Raf, ERK

CLC Number:

R392.2

ZHANG Xiaowan, KANG Xia, YAO Xiaoying, XIE Fang, LI Ying. Silencing SF3B1 promotes apoptosis and inhibits proliferation and invasion of human lung cancer cell line A549[J]. Basic & Clinical Medicine, 2023, 43(8): 1265-1270.

References 12

[1]	卫群芳,朱丽媛,韩为,等.胶质瘤中PTB调控长非编码RNA选择性剪接的筛选[J].基础医学与临床,2018,38:787-792.
[2]	Raquel VN, Tarin M, Canbezdi C, et al. Glycolysis dependency as a hallmark of SF3B1-mutated cells[J]. Cancers (Basel), 2022, 14: 2113.doi: 10.3390/cancers14092113.
[3]	Yang T, Wang L, Zhang Y. Letter to the editor regarding the article “prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: a meta-analysis”[J]. Crit Rev Oncol Hematol, 2021, 162:103295.doi: 10.1016/j.critrevonc.2021.103295.
[4]	Lieu YK, Liu Z, Ali AM, et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes[J]. Proc Natl Acad Sci U S A, 2022, 119: e2111703119.doi: 10.1073/pnas.2111703119.
[5]	Popli P, Richters MM, Chadchan SB, et al. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation[J]. Cell Death Dis, 2020, 11: 842.doi: 10.1038/s41419-020-03055-y.
[6]	Yang JY, Huo YM, Yang MW, et al. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis[J]. Mol Oncol, 2021, 15: 3076-3090.
[7]	Fuentes AC, Pérez JM, García ME, et al. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/β-catenin pathways imbalances[J]. J Exp Clin Cancer Res, 2022, 41: 39. doi: 10.1186/s13046-022-02241-4.
[8]	Lopez JL, Rio MD, Fernandez H, et al. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma[J]. Cancer Letters, 2020, 496:72-93.
[9]	Zhang QJ, Di CX, Yan JF, et al. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells[J]. Artif Cells Nanomed Biotechnol, 2019, 47:1273-1280.
[10]	Vacas JM, Aguayo VH, Gómez E, et al. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer[J]. Transl Res, 2019, 212:89-103.
[11]	Ling Z, Xiaojuan Z, Haitao, et al. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing[J]. Breast cancer, 2020, 27:464-476.
[12]	Wang YH, Xu H, Lu ZY, et al. Pseudo-Ginsenoside Rh2 induces A549 cells apoptosis via the Ras/Raf/ERK/p53 pathway[J]. Exp Ther Med, 2018, 15: 4916-4924.

[1]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[2]	WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng. Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation [J]. Basic & Clinical Medicine, 2024, 44(6): 866-872.
[3]	YE Yuxin, LI Huixian, YAN Tao, ZHANG Yun, SUN Yulin. Quantitative analysis of trace-level proteins for assessing inflammation through clinical sampling [J]. Basic & Clinical Medicine, 2024, 44(5): 690-698.
[4]	YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei. Research progress of phosphodiesterase 5 in heart failure [J]. Basic & Clinical Medicine, 2024, 44(5): 724-728.
[5]	CHEN Si, ZHANG Jiao, ZHANG Yuelun, CUI Xulei, TAN Gang. Effect of ultrasound scanning route map on the learning effectiveness of cervical ultrasound for beginners [J]. Basic & Clinical Medicine, 2024, 44(4): 572-576.
[6]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[7]	YANG Kaifei, ZHU Jingge, ZHANG Yangyang, ZHAO Junguo, GAO Yuyue, HU Huanhuan, JI Guojie. Effect of sorafenib induced apoptosis and autophagy on drug resistance in HeLa cells [J]. Basic & Clinical Medicine, 2024, 44(4): 467-473.
[8]	LI Na, LI Tao, YANG Dongli, YAO Yuan. Honokiol inhibits the proliferation of human adipose-derived mesenchymal stem cells [J]. Basic & Clinical Medicine, 2024, 44(4): 483-488.
[9]	HAN Huijing, WU Hong, GE Yin, QIAO Juan. Dexmedetomidine alleviates lung tissue injury of rat models with ventilator-associated lung injury [J]. Basic & Clinical Medicine, 2024, 44(3): 339-345.
[10]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[11]	HU Zijin, KONG Yan, WU Xiaowen, GUO Qian, GUO Jun. Effect and mechanism of Sitravatinib combined with Niraparib on proliferation, apoptosis and autophagy in mucosal melanoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(3): 295-302.
[12]	CHEN Xue, LUO Tian, WEI Chaojun. Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors [J]. Basic & Clinical Medicine, 2024, 44(2): 256-259.
[13]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[14]	DING Fei, WANG Sa, HUANG Changxin. Serum CA211 level and NK cell number are associated with prognosis of patients with non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 180-184.
[15]	. Role of TERT in regulating mitochondrial oxidative stress in diseases [J]. Basic & Clinical Medicine, 2024, 44(10): 1436-1441.